EB FlevoResearch B.V.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At EB FlevoResearch B.V. in Almere, clinical research in cardiovascular diseases focuses on major heart and blood vessel conditions such as atherosclerotic cardiovascular disease, elevated Lp(a), and broader atherosclerosis-related risk. These studies are designed to assess whether new therapies can reduce serious cardiovascular events and improve long-term outcomes.
- Testing treatments aimed at lowering the risk of major heart-related complications
- Evaluating approaches for people with established cardiovascular disease and high risk factors
- Studying therapies intended to reduce events such as heart attack and stroke
This area also includes research linking cardiovascular health with kidney outcomes, reflecting a broader effort to improve prevention and treatment for people with complex chronic disease.
Nutritional and Metabolic Diseases
Research in nutritional and metabolic diseases at this site centers on obesity, overweight, and type 2 diabetes mellitus. The trials are mainly exploring whether new therapies can support weight reduction, improve metabolic control, and lower the risk of complications tied to excess body weight and diabetes.
- Assessing treatments for weight loss and weight management
- Studying therapies for people with type 2 diabetes and elevated cardiovascular risk
- Evaluating whether metabolic treatments can improve long-term health outcomes
These studies reflect a strong interest in the overlap between metabolic health and cardiovascular prevention, with the goal of improving care for people living with multiple related conditions.
Respiratory Tract Diseases
The respiratory tract diseases portfolio includes trials in asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis. Research here is focused on improving symptom control and reducing flare-ups in people with ongoing breathing problems.
- Testing new options for asthma control in adults with more severe disease
- Evaluating add-on treatments for COPD to reduce exacerbations
- Supporting research aimed at better management of chronic lung disease
Overall, the respiratory studies at EB FlevoResearch B.V. are aimed at finding more effective ways to prevent worsening disease and improve day-to-day respiratory health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Eli Lilly & Co.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in EB FlevoResearch B.V.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents aged 6 to 17 Years with Attention-deficit/Hyperactivity Disorder | Takeda Development Center Americas Inc. | Phase III | Not Recruiting | Nov 2019 | Sep 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atomoxetine Hydrochloride | 1 | Unknown | 2019-11-20 | 2019-11-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.